Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633609 | 0.77 | IRAK4 (0.47) | MAPK1LRRK2IRAK4JAK2JAK1 | |
| SCHEMBL29944842 | 0.74 | EML4 (0.44) | MAPK1PDE4BEML4ALK | |
| SCHEMBL30151513 | 0.73 | EML4 (0.50) | PDE4BEML4ALKIRAK4JAK2 | |
| SCHEMBL25507990 | 0.71 | LRRK2 (0.45) | MAPK1LRRK2PDE4BPDE7AEML4 | |
| SCHEMBL26179066 | 0.69 | MAPK1 (0.47) | MAPK1LRRK2PDE4BJAK2JAK1 | |
| SCHEMBL23186839 | 0.69 | LRRK2 (0.54) | MAPK1LRRK2IRAK4PDE10AJAK2 | |
| SCHEMBL16220909 | 0.69 | MAPK1 (0.58) | MAPK1LRRK2MAPK8MAPK9MAPK10 | |
| SCHEMBL22573150 | 0.69 | MAPK1 (0.40) | MAPK1LRRK2PDE4BPDE7AEML4 | |
| SCHEMBL31498507 | 0.69 | BTK (0.49) | MAPK1LRRK2PDE4BEML4ALK | |
| SCHEMBL6444159 | 0.68 | LRRK2 (0.38) | MAPK1LRRK2PDE4BPDE7AEML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | MAPK1 1790/4885LRRK2 1393/4885PDE4B 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.